Gregory M. Glenn

2017

In 2017, Gregory M. Glenn earned a total compensation of $1.2M as President, Research and Development at Novavax, a 26% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$229,500
Option Awards$531,250
Salary$450,000
Other$10,500
Total$1,221,250

Glenn received $531.3K in option awards, accounting for 44% of the total pay in 2017.

Glenn also received $229.5K in non-equity incentive plan, $450K in salary and $10.5K in other compensation.

Rankings

In 2017, Gregory M. Glenn's compensation ranked 8,024th out of 14,666 executives tracked by ExecPay. In other words, Glenn earned more than 45.3% of executives.

ClassificationRankingPercentile
All
8,024
out of 14,666
45th
Division
Manufacturing
3,019
out of 5,772
48th
Major group
Chemicals And Allied Products
989
out of 2,075
52nd
Industry group
Drugs
773
out of 1,731
55th
Industry
Biological Products, Except Diagnostic Substances
141
out of 313
55th
Source: SEC filing on April 30, 2018.

Glenn's colleagues

We found four more compensation records of executives who worked with Gregory M. Glenn at Novavax in 2017.

2017

Stanley Erck

Novavax

Chief Executive Officer

2017

John Trizzino

Novavax

SVP, Commercial Operations

2017

John Herrmann

Novavax

General Counsel

2017

Barclay Phillips

Novavax

Chief Financial Officer

News

You may also like